Based on the Nurix Therapeutics Inc stock forecast from 12 analysts, the average analyst target price for Nurix Therapeutics Inc is USD 31.14 over the next 12 months. Nurix Therapeutics Inc’s average analyst rating is Strong Buy. Stock Target Advisor’s own stock analysis of Nurix Therapeutics Inc is Bearish, which is based on 1 positive signals and 6 negative signals. At the last closing, Nurix Therapeutics Inc’s stock price was USD 9.72. Nurix Therapeutics Inc’s stock price has changed by -18.18% over the past week, -29.87% over the past month and -29.57% over the last year.
No recent analyst target price found for Nurix Therapeutics Inc
No recent average analyst rating found for Nurix Therapeutics Inc
Company Overview Nurix Therapeutics Inc
Nurix Therapeutics, Inc., a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule and antibody therapies for the treatment of cancer, inflammatory conditions, and other diseases. The company develops NX-5948, an orally bioavailable BTK degrader, that is in Phase 1B/2 clinical trials for the treatment of relapsed or refractory B-cell malignancies and autoimmune diseases; NX-2127, an orally bioavailable Bruton's tyrosine kinase (BTK) degrader, that is in Phase 1A clinical trials for the treatment of relapsed or refractory B-cell malignancies; and NX-1607, an orally bioavailable Casitas B-lineage lymphoma proto-oncogene-B (CBL-B) inhibitor, that is in Phase 1A clinical trials to treat immuno-oncology indications. It is also developing NX 0479/GS 6791, a IRAK4 degrader for the treatment of rheumatoid arthritis and other inflammatory diseases. The company has a strategic collaboration agreement with Gilead Sciences, Inc. (Gilead), Sanofi S.A. (Sanofi), and Pfizer Inc. (Pfizer) for co-development and co-commercialization for multiple drug candidates. The company was formerly known as Nurix Inc. and changed its name to Nurix Therapeutics, Inc. in October 2018. Nurix Therapeutics, Inc. was incorporated in 2009 and is headquartered in San Francisco, California. Read Less
Nurix Therapeutics, Inc., a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule and antibody therapies for the treatment of cancer, inflammatory conditions, and other diseases. The company develops NX-5948, an o...Read More
Frequently Asked Questions About Nurix Therapeutics Inc (NRIX) Stock
Based on ratings from 12 analysts Nurix Therapeutics Inc's stock is Strong Buy. Stock Target Advisor's fundamental analysis is Bearish. The stock has 19 buy, sell and 2 hold ratings.
Unfortunately we do not have enough data on NRIX's stock to indicate if its a good dividend stock.
Based on targets from 12 analysts, the average taret price for NRIX is USD 31.14 over the next 12 months. The maximum analyst target price is USD 36 while the minimum anlayst target price is USD 16.
Unfortunately we do not have enough data on NRIX's stock to indicate if its overvalued.
The last closing price of NRIX's stock was USD 9.72.
The most recent market capitalization for NRIX is USD 1.05B.
Based on targets from 12 analysts, the average taret price for NRIX is projected at USD 31.14 over the next 12 months.
This means that NRIX's stock price may go up by +220.40% over the next 12 months.
We can't find any ETFs which contains Nurix Therapeutics Inc's stock.
As per our most recent records Nurix Therapeutics Inc has 286 Employees.
Nurix Therapeutics Inc's registered address is 1700 Owens Street, San Francisco, CA, United States, 94158.
You can get more information about it from Nurix Therapeutics Inc's website at https://www.nurixtx.com.
Heading 1
Heading 2
Heading 3
Heading 4
Heading 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Stock Target Advisor's Analysis
This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.
What to like
High market capitalization
This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.
What not to like
Overpriced compared to book value
The stock is trading high compared to its peers median on a price to book value basis.
High volatility
The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.
Negative cashflow
The company had negative total cash flow in the most recent four quarters.
Negative free cash flow
The company had negative total free cash flow in the most recent four quarters.
Low Revenue Growth
This stock has shown below median revenue growth in the previous 5 years compared to its sector
Low Earnings Growth
This stock has shown below median earnings growth in the previous 5 years compared to its sector
Frequently Asked Questions About Nurix Therapeutics Inc (NRIX) Stock
Based on ratings from 12 analysts Nurix Therapeutics Inc's stock is Strong Buy. Stock Target Advisor's fundamental analysis is Bearish. The stock has 19 buy, sell and 2 hold ratings.
Unfortunately we do not have enough data on NRIX's stock to indicate if its a good dividend stock.
Based on targets from 12 analysts, the average taret price for NRIX is USD 31.14 over the next 12 months. The maximum analyst target price is USD 36 while the minimum anlayst target price is USD 16.
Unfortunately we do not have enough data on NRIX's stock to indicate if its overvalued.
The last closing price of NRIX's stock was USD 9.72.
The most recent market capitalization for NRIX is USD 1.05B.
Based on targets from 12 analysts, the average taret price for NRIX is projected at USD 31.14 over the next 12 months.
This means that NRIX's stock price may go up by +220.40% over the next 12 months.
We can't find any ETFs which contains Nurix Therapeutics Inc's stock.
As per our most recent records Nurix Therapeutics Inc has 286 Employees.
Nurix Therapeutics Inc's registered address is 1700 Owens Street, San Francisco, CA, United States, 94158.
You can get more information about it from Nurix Therapeutics Inc's website at https://www.nurixtx.com.
Add to Watchlists
loading..
Thank you for Sharing your Stock Targets for NRIX !
Loading...
Please login to proceed
Sorry - extended search is only available for registered users.
